Southern California entrepreneur Manny Bojorquez has guided growth firms to successful outcomes in a variety of industries spanning legal, medical advice, and automotive performance. In the latter sphere, Manny Bojorquez leads HyperCar Development, where, as its owner and operator, he customizes rugged vehicles such as the Ford Raptor off-road truck.The 2019 Ford F-150 Raptor is designed to do well in various rough-terrain situations, including trails and dry lakebeds. With standard Trail Control, the driver does not need to brake or throttle, as the technology allows the vehicle to tackle slopes and inclines at optimal speed.The Fox shocks hold up admirably in any terrain, while the Live Valve system offers an electronic adjusting damper. Taking in inputs such as steering, brakes, throttle, and road conditions, the vehicle adjusts in real time for peak performance. A new option is Recaro seats with Alcantara inserts that take the classic Ford GT supercar as their inspiration.HyperCar Development’s upgrade selections for the Ford Raptor include carbon fiber hood vents, offroad tuning modules, and side exit exhaust systems.
Based in California, entrepreneur Manny Bojorquez has launched multiple companies including HyperCar Development and ZipTuning USA. In addition, Manny Bojorquez oversees operations for the all-natural pharmaceutical development business peaCURE. Striving to become a leader in science-based approaches to natural healing, the company combines research-proven ingredients with purity testing to produce effective pharmaceuticals.The company’s proprietary product is a line of supplements and medical foods containing pure palmitoylethanolamide (PEA), a fatty acid amide that naturally occurs in the body. Its production appears to be a response to inflammation, and it interferes with processes involved with chronic pain and inflammation by binding to the receptors in the cell's nucleus. Studies on PEA indicate that it can benefit individuals with afflictions such as peripheral neuropathy, fibromyalgia, and chronic regional pain syndrome (CRPS) by blocking or inhibiting the systems that trigger pain receptors. Although other countries began research on PEA’s potential as an alternative to opioids in treating chronic pain conditions decades ago, its use and appeal is only now steadily gaining traction in medical circles within the US. This growing interest has led to new research and clinical trials on PEA-based medications and treatments, peaCURE among them. Its appeal largely stems from its lack of side effects and inability to cause an overdose, since the substance is found naturally inside the body. For more information on peaCURE, visit peacure.com.
